Effectiveness of Nirmatrelvir-Ritonavir for the Prevention of COVID-19-Related Hospitalization and Mortality: A Systematic Literature Review
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Nirmatrelvir/ritonavir (NMV/r) significantly reduces COVID-19 hospitalization and death in high-risk patients. This oral antiviral is effective across diverse patient groups and follow-up durations, confirming its value in real-world settings.
Area Of Science
- Infectious Diseases
- Pharmacology
- Public Health
Background
- Nirmatrelvir/ritonavir (NMV/r) is an oral antiviral for mild-to-moderate COVID-19 in high-risk individuals aged 12+.
- Despite being a preferred outpatient treatment globally, NMV/r is underutilized in clinical practice.
Purpose Of The Study
- To systematically review real-world evidence on NMV/r effectiveness against hospitalization and mortality.
- To organize findings by patient demographics and follow-up duration to inform healthcare decisions.
Main Methods
- Systematic literature review of Embase, PubMed, and congress abstracts (December 2021-March 2023).
- Inclusion of 18 real-world studies assessing NMV/r effectiveness.
Main Results
- NMV/r significantly reduced all-cause and COVID-19-related hospitalization and mortality (acute: 21%-92%; longer-term: 1%-61%).
- Effectiveness was higher when treatment initiated within 5 days of symptom onset.
- Real-world effectiveness was consistent across age groups, underlying conditions, and vaccination status.
Conclusions
- NMV/r demonstrates effectiveness in preventing hospitalization and mortality during the Omicron period for high-risk COVID-19 patients.
- Findings support NMV/r as a valuable tool for managing severe COVID-19 outcomes in real-world settings.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
